drugset
drugset / Trial / NCT05674474

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

NCT05674474 ↗

Phase 1 Completed 16 enrolled Servier
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to estimate the effect of moderate or mild hepatic impairment on the pharmacokinetic (PK) profile of a single oral dose of 20 mg vorasidenib in participants with hepatic impairment relative to healthy matched control participants with normal hepatic function.

Timeline

Start
2023-03-14
Primary completion
2023-07-18
Completion
2023-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorasidenib Small molecule 20 mg Oral

Indications

No indication recorded.